During the corresponding time, Longduoduo Co Ltd saw a revenue deteriorated by -32.9 % year on year, sequentially revenue grew by 236.73 %. While revenue at the Longduoduo Co Ltd's corporate clients
Longduoduo Co Ltd's Comment on Sales, Marketing and Customers
Longduoduo's operating subsidiaries—Longduoduo Health Technology, Qingguo, Rongbin, Chengheng, and Tianju—function as sales agents or distributors for third-party healthcare service providers. They specialize in preventive healthcare solutions addressing myocardial infarction, cerebral infarction, hemiplegia, cardiovascular and cerebrovascular diseases, and gastrointestinal digestive disorders. Since June 2023, more than 99.6% of the company's gross revenue has been derived from commissions earned through agency agreements with Inner Mongolia Honghai Health Management Co., Ltd. (Honghai), agreements that are set to expire in 2029. Honghai develops and offers services including Immunological Ozonated Autohemotherapy, Meridian-regulating and Consciousness-restoring iatrotechnics, double blood purification, gut microbiota products, and gut testing services, which the subsidiaries promote and sell. Previously, the subsidiaries operated as principals by purchasing and reselling services from third-party providers such as hospitals to customers in Hohhot, Ordos, Baotou, and Ulanqab in Inner Mongolia; however, revenue from these principal sales declined significantly by June 30, 2026.
Longduoduo Co Ltd’s Comment on Sales, Marketing and Customers
Longduoduo's operating subsidiaries—Longduoduo Health Technology, Qingguo, Rongbin, Chengheng, and Tianju—function as sales agents or distributors for third-party healthcare service providers. They specialize in preventive healthcare solutions addressing myocardial infarction, cerebral infarction, hemiplegia, cardiovascular and cerebrovascular diseases, and gastrointestinal digestive disorders. Since June 2023, more than 99.6% of the company's gross revenue has been derived from commissions earned through agency agreements with Inner Mongolia Honghai Health Management Co., Ltd. (Honghai), agreements that are set to expire in 2029. Honghai develops and offers services including Immunological Ozonated Autohemotherapy, Meridian-regulating and Consciousness-restoring iatrotechnics, double blood purification, gut microbiota products, and gut testing services, which the subsidiaries promote and sell. Previously, the subsidiaries operated as principals by purchasing and reselling services from third-party providers such as hospitals to customers in Hohhot, Ordos, Baotou, and Ulanqab in Inner Mongolia; however, revenue from these principal sales declined significantly by June 30, 2026.
Sources:
Longduoduo Co Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Longduoduo Co Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Longduoduo Co Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
1.11 %